

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

PROFIT WARNING

This announcement is made by Tongfang Kontafarma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Group that, based on the latest unaudited consolidated management accounts of the Group for the year ended 31 December 2020 (the “**FY 2020**”) and the latest information available to the Board, the Group is expected to record a consolidated net loss in the region of approximately HK\$195 million to HK\$235 million for the FY 2020, compared to the consolidated net profit of approximately HK\$65 million for the year ended 31 December 2019. Such change was mainly attributable to: (i) the loss as a result of the disposal of the entire interest in Real Jade Limited, being the then holding company of the cement business of the Group, in December 2020; and (ii) the expected impairment loss on property, plant and equipment used in the then cement business of the Group.

The information in this announcement is based on a preliminary assessment by the management of the Company with reference to the unaudited consolidated management accounts of the Group for the FY 2020. Such information has not been finalised, audited or reviewed by the Company’s independent auditor, and has not been confirmed by the audit committee of the Board. The finalised audited consolidated results of the Group for the FY 2020 are expected to be announced by the end of March 2021, which may differ from the figures and information provided in this announcement.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Chai Hongjie
Chairman

Hong Kong, 18 March 2021

As at the date of this announcement, the Board comprises four executive directors, namely Mr. Chai Hongjie (Chairman), Mr. Huang Yu (President), Mr. Wei Bingzhang and Mr. Jiang Chaowen (Chief Executive Officer) and three independent non-executive directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.